Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Virology Journal
Published in: Virology Journal 1/2022

Open Access 01-12-2022 | SARS-CoV-2 | Research

SNPs of ACE1 (rs4343) and ACE2 (rs2285666) genes are linked to SARS-CoV-2 infection but not with the severity of disease

Authors: Nahid Alimoradi, Moein Sharqi, Dena Firouzabadi, Mohammad Moein Sadeghi, Mohammad Iman Moezzi, Negar Firouzabadi

Published in: Virology Journal | Issue 1/2022

Login to get access

Abstract

COVID-19 and the renin-angiotensin system (RAS) are linked by angiotensin-converting enzyme 2 (ACE2), a key enzyme in RAS that has been validated as a SARS-CoV-2 receptor. Functional ACE1/ACE2 gene polymorphisms may lead to the imbalance between ACE/ACE2 ratio and thus generating RAS imbalance that is associated with higher degrees of lung damage in ARDS that may contribute to the COVID-19 infection outcome. Herein, we investigated the role of RAS gene polymorphisms, ACE1 (A2350G) and ACE2 (G8790A) as risk predictors for susceptibility and severity of COVID-19 infection. A total of 129 included: negative controls without a history of COVID-19 infection (n = 50), positive controls with a history of COVID-19 infection who were not hospitalized (n = 35), and patients with severe COVID-19 infection who were hospitalized in the intensive care unit (n = 44). rs4343 of ACE and rs2285666 of ACE2 were genotyped using PCR–RFLP method. Our results indicated that susceptibility to COVID-19 infection was associated with age, GG genotype of A2350G (Pa = 0.01; OR 4.7; 95% CI 1.4–15.1 and Pc = 0.040; OR 2.5; 95% CI 1.05–6.3) and GG genotype of G8790A (Pa = 0.044; OR 6.17; 95% CI 1.05–35.71 and Pc = 0.0001; OR 5.5; 95% CI 2.4–12.4). The G allele of A2350G (Pa = 0.21; OR 1.74; 95% CI 0.73–4.17 and Pc = 0.007; OR 2.1; 95% CI 1.2–3.5) and G allele of G8790A (Pa = 0.002; OR 4.26; 95% CI 1.7–10.65 and Pc = 0.0001; OR 4.7; 95% CI 2.4–9.2) were more frequent in ICU-admitted patients and positive control group. Also lung involvement due to COVID-19 infection was associated with age and the comorbidities such as diabetes. In conclusion, our findings support the association between the wild genotype (GG) of ACE2 and homozygote genotype (GG) of ACE1 and sensitivity to COVID-19 infection, but not its severity. However, confirmation of this hypothesis requires further studies with more participants.
Literature
1.
Yang, W., et al. (2020) The role of imaging in 2019 novel coronavirus pneumonia (COVID-19). European radiology 30: 1-9.
2.
3.
4.
Shang, J., et al., Structure of 2019-nCoV chimeric receptor-binding domain complexed with its receptor human ACE2. Worldw. Protein Data Bank (2020).
5.
6.
Li F. Receptor recognition mechanisms of coronaviruses: a decade of structural studies. J Virol. 2015;89(4):1954–64.PubMedCrossRef
7.
8.
Bahramali E, et al. Association of ACE gene D polymorphism with left ventricular hypertrophy in patients with diastolic heart failure: a case–control study. BMJ Open. 2016;6(2):e010282.PubMedPubMedCentralCrossRef
9.
Sekuri C, et al. Renin-angiotensin system gene polymorphisms and premature coronary heart disease. J Renin Angiotensin Aldosterone Syst. 2005;6(1):38–42.PubMedCrossRef
10.
11.
Vaduganathan M, et al. Renin–angiotensin–aldosterone system inhibitors in patients with Covid-19. N Engl J Med. 2020;382(17):1653–9.PubMedCrossRef
12.
Ferrario CM. The renin-angiotensin system: importance in physiology and pathology. J Cardiovasc Pharmacol. 1990;15:S1-5.PubMedCrossRef
13.
Li X, et al. Impact of cardiovascular disease and cardiac injury on in-hospital mortality in patients with COVID-19: a systematic review and meta-analysis. Heart. 2020;106(15):1142–7.PubMedCrossRef
14.
Sabatino J, et al. Impact of cardiovascular risk profile on COVID-19 outcome. A meta-analysis. PLoS ONE. 2020;15(8):1023.CrossRef
15.
Shamshirian, A., et al., Cardiovascular diseases and COVID-19 mortality and intensive care unit admission: A systematic review and meta-analysis. medRxiv, 2020.
16.
Shenoy V, et al. The angiotensin-converting enzyme 2/angiogenesis-(1–7)/Mas axis confers cardiopulmonary protection against lung fibrosis and pulmonary hypertension. Am J Respir Crit Care Med. 2010;182(8):1065–72.PubMedPubMedCentralCrossRef
17.
Wösten-van Asperen RM, et al. Acute respiratory distress syndrome leads to reduced ratio of ACE/ACE2 activities and is prevented by angiotensin-(1–7) or an angiotensin II receptor antagonist. J Pathol. 2011;225(4):618–27.PubMedCrossRef
18.
Yan F, et al. Antihypertensive drugs are associated with reduced fatal outcomes and improved clinical characteristics in elderly COVID-19 patients. Cell Discov. 2020;6(1):1–10.CrossRef
19.
Yang, G., et al., Angiotensin II receptor blockers and angiotensin-converting enzyme inhibitors usage is associated with improved inflammatory status and clinical outcomes in COVID-19 patients with hypertension. MedRxiv, 2020.
20.
Sun, M., et al., Inhibitors of RAS might be a good choice for the therapy of COVID-19 pneumonia. Zhonghua jie he he hu xi za zhi= Zhonghua jiehe he huxi zazhi= Chinese journal of tuberculosis and respiratory diseases, 2020. 43:E014-E014.
21.
Wu J, et al. Advances in research on ACE2 as a receptor for 2019-nCoV. Cell Mol Life Sci. 2021;78(2):531–44.PubMedCrossRef
22.
Letko M, Marzi A, Munster V. Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses. Nat Microbiol. 2020;5(4):562–9.PubMedCrossRef
23.
Costa LB, et al. Insights on SARS-CoV-2 molecular interactions with the renin-angiotensin system. Front Cell Dev Biol. 2020;8:55.CrossRef
24.
Hamming I, et al. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J Pathol J Pathol Soc Great Britain Ireland. 2004;203(2):631–7.
25.
Donoghue M, et al. A novel angiotensin-converting enzyme–related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1–9. Circ Res. 2000;87(5):e1–9.PubMedCrossRef
26.
Vickers C, et al. Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase. J Biol Chem. 2002;277(17):14838–43.PubMedCrossRef
27.
Chappel M, Ferrario C. ACE and ACE2: their role to balance the expression of angiotensin II and angiotensin-(1–7). Kidney Int. 2006;70(1):8–10.PubMedCrossRef
28.
Leisman DE, Deutschman CS, Legrand M. Facing COVID-19 in the ICU: vascular dysfunction, thrombosis, and dysregulated inflammation. Intensive Care Med. 2020;46(6):1105–8.PubMedPubMedCentralCrossRef
29.
Liu Z, et al. Composition and divergence of coronavirus spike proteins and host ACE2 receptors predict potential intermediate hosts of SARS-CoV-2. J Med Virol. 2020;92(6):595–601.PubMedCrossRef
30.
Liu Y, et al. Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury. Sci China Life Sci. 2020;63(3):364–74.PubMedPubMedCentralCrossRef
31.
Nukiwa T, et al. Responses of serum and lung angiotensin-converting enzyme activities in the early phase of pulmonary damage induced by oleic acid in dogs. Am Rev Respir Dis. 1982;126(6):1080–6.PubMed
32.
Dandona P, et al. Angiotensin II and inflammation: the effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockade. J Hum Hypertens. 2007;21(1):20–7.PubMedCrossRef
33.
34.
35.
Chaoxin J, et al. The influence of angiotensin-converting enzyme 2 gene polymorphisms on type 2 diabetes mellitus and coronary heart disease. Eur Rev Med Pharmacol Sci. 2013;17(19):2654–9.PubMed
36.
Gemmati D, Tisato V. Genetic hypothesis and pharmacogenetics side of renin-angiotensin-system in COVID-19. Genes. 2020;11(9):1044.PubMedCentralCrossRef
37.
Alimoradi N, Firouzabadi N. impact of genetics on predisposition and prognosis of COVID-19. Trends Pharmaceut Sci. 2021;7(2):10.
38.
Barash A, et al. The pursuit of COVID-19 biomarkers: putting the spotlight on ACE2 and TMPRSS2 regulatory sequences. Front Med. 2020;7:10.CrossRef
39.
Srivastava A, et al. Genetic association of ACE2 rs2285666 polymorphism with COVID-19 spatial distribution in India. Front Genet. 2020;11:1163.CrossRef
40.
Çelik, S.K., et al., Polymorphisms of ACE (I/D) and ACE2 receptor gene (Rs2106809, Rs2285666) are not related to the clinical course of COVID-19; a case study. J Med Virol 2021.
41.
Patel SK, et al. From gene to protein—experimental and clinical studies of ACE2 in blood pressure control and arterial hypertension. Front Physiol. 2014;5:227.PubMedPubMedCentralCrossRef
42.
Calcagnile M, et al. Molecular docking simulation reveals ACE2 polymorphisms that may increase the affinity of ACE2 with the SARS-CoV-2 Spike protein. Biochimie. 2021;180:143–8.PubMedCrossRef
43.
Ashoor, D., et al., A computational approach to evaluate the combined effect of SARS-CoV-2 RBD mutations and ACE2 receptor genetic variants on infectivity: The COVID-19 host-pathogen nexus. bioRxiv, 2021: p. 2020.10. 23.352344.
44.
Pouladi N, Abdolahi S. Investigating the ACE2 polymorphisms in COVID-19 susceptibility: an in silico analysis. Mol Genet Genomic Med. 2021;10:e1672.
45.
Firouzabadi N, et al. Interaction of A-240T and A2350G related genotypes of angiotensin-converting enzyme (ACE) is associated with decreased serum ACE activity and blood pressure in a healthy Iranian population. Eur J Pharmacol. 2011;668(1–2):241–7.PubMedCrossRef
46.
Firouzabadi N, et al. Association of angiotensin-converting enzyme (ACE) gene polymorphism with elevated serum ACE activity and major depression in an Iranian population. Psychiatry Res. 2012;200(2–3):336–42.PubMedCrossRef
47.
Zhu X, et al. Linkage and association analysis of angiotensin I–converting enzyme (ACE)–gene polymorphisms with ACE concentration and blood pressure. Am J Human Genet. 2001;68(5):1139–48.CrossRef
48.
49.
Leger T, et al. Low-dose chest CT for diagnosing and assessing the extent of lung involvement of SARS-CoV-2 pneumonia using a semi quantitative score. PLoS ONE. 2020;15(11):e0241407.PubMedPubMedCentralCrossRef
50.
MWer S, Dykes D, Polesky H. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 1988;16(3):1215.CrossRef
51.
Zhong J, et al. Association of angiotensin-converting enzyme 2 gene A/G polymorphism and elevated blood pressure in Chinese patients with metabolic syndrome. J Lab Clin Med. 2006;147(2):91–5.PubMedPubMedCentralCrossRef
52.
Iqbal MP, et al. Association study of the angiotensin-converting enzyme (ACE) gene G2350A dimorphism with myocardial infarction. Exp Mol Med. 2004;36(2):110–5.PubMedCrossRef
53.
Firouzabadi N, et al. Impact of ACE 2 genetic variant on antidepressant efficacy of SSRIs. Acta Neuropsychiatrica. 2021;10:1–25.
54.
Firouzabadi N, et al. Gender specificity of a genetic variant of angiotensin-converting enzyme and risk of coronary artery disease. Mol Biol Rep. 2013;40(8):4959–65.PubMedCrossRef
55.
56.
Wang, Q., et al., Structural and functional basis of SARS-CoV-2 entry by using human ACE2. Cell, 2020;181(4):894–904. e9.
57.
Santos RAS, et al. The ACE2/angiotensin-(1–7)/MAS axis of the renin-angiotensin system: focus on angiotensin-(1–7). Physiol Rev. 2017;98:505–53.PubMedCentralCrossRef
58.
Xu H, et al. High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa. Int J Oral Sci. 2020;12(1):1–5.CrossRef
59.
Rice GI, et al. Evaluation of angiotensin-converting enzyme (ACE), its homologue ACE2 and neprilysin in angiotensin peptide metabolism. Biochem J. 2004;383(1):45–51.PubMedPubMedCentralCrossRef
60.
Li Y, et al. Angiotensin-converting enzyme 2 prevents lipopolysaccharide-induced rat acute lung injury via suppressing the ERK1/2 and NF-κB signaling pathways. Sci Rep. 2016;6(1):1–14.
61.
Magalhaes GS, et al. Angiotensin-(1–7) promotes resolution of eosinophilic inflammation in an experimental model of asthma. Front Immunol. 2018;9:58.PubMedPubMedCentralCrossRef
62.
Wang D, et al. Renin-angiotensin-system, a potential pharmacological candidate, in acute respiratory distress syndrome during mechanical ventilation. Pulmonary Pharmacol Therapeut. 2019;58:101.CrossRef
63.
He H, et al. Mesenchymal stem cells overexpressing angiotensin-converting enzyme 2 rescue lipopolysaccharide-induced lung injury. Cell Transplant. 2015;24(9):1699–715.PubMedCrossRef
64.
Bastos AC, et al. Oral formulation angiotensin-(1–7) therapy attenuates pulmonary and systemic damage in mice with emphysema induced by elastase. Immunobiology. 2020;225(2):151893.PubMedCrossRef
65.
66.
Magalhaes GS, et al. Activation of Ang-(1–7)/Mas receptor is a possible strategy to treat coronavirus (SARS-CoV-2) infection. Front Physiol. 2020;11:730.PubMedPubMedCentralCrossRef
67.
Chappell MC, Al Zayadneh EM. Angiotensin-(1–7) and the regulation of anti-fibrotic signaling pathways. J Cell Signal. 2017;2(1):10.CrossRef
68.
Gironacci MM. Angiotensin-(1–7): beyond its central effects on blood pressure. Ther Adv Cardiovasc Dis. 2015;9(4):209–16.PubMedCrossRef
69.
70.
Wu YH, et al. The ACE 2 G8790A polymorphism: involvement in type 2 diabetes mellitus combined with cerebral stroke. J Clin Lab Anal. 2017;31(2):e22033.CrossRef
71.
Wang Z, et al. Immune responses with DNA vaccines encoded different gene fragments of severe acute respiratory syndrome coronavirus in BALB/c mice. Biochem Biophys Res Commun. 2005;327(1):130–5.PubMedCrossRef
72.
Möhlendick B, et al. ACE2 polymorphism and susceptibility for SARS-CoV-2 infection and severity of COVID-19. Pharmacogenet Genom. 2021;31:165–71.CrossRef
73.
Karakaş Çelik S, et al. Polymorphisms of ACE (I/D) and ACE2 receptor gene (Rs2106809, Rs2285666) are not related to the clinical course of COVID-19: a case study. J Med Virol. 2021;93(10):5947–52.PubMedPubMedCentralCrossRef
74.
75.
76.
77.
78.
Hoffmann, M., et al., SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 2020;181(2):271–280.e8.
79.
Walls, A.C., et al., Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell, 2020;181(2): 281–292.e6.
80.
Mahmood MS, et al. Association of the angiotensin-converting enzyme (ACE) gene G2350A dimorphism with essential hypertension. J Hum Hypertens. 2003;17(10):719–23.CrossRef
81.
Schüler R, et al. High-saturated-fat diet increases circulating angiotensin-converting enzyme, which is enhanced by the rs4343 polymorphism defining persons at risk of nutrient-dependent increases of blood pressure. J Am Heart Assoc. 2017;6(1):e004465.PubMedPubMedCentralCrossRef
82.
Watanabe T, Barker TA, Berk BC. Angiotensin II and the endothelium: diverse signals and effects. Hypertension. 2005;45(2):163–9.PubMedCrossRef
83.
Senchenkova EY, et al. Angiotensin II–mediated microvascular thrombosis. Hypertension. 2010;56(6):1089–95.PubMedCrossRef
84.
Tay K-H, Lip GY. What “drives” the link between the renin–angiotensin–aldosterone system and the prothrombotic state in hypertension? Oxford: Oxford University Press; 2008.CrossRef
85.
86.
Biswas S, et al. Blood clots in COVID-19 patients: simplifying the curious mystery. Med Hypotheses. 2021;146:110371.PubMedCrossRef
87.
Ferreira AJ, et al. New cardiovascular and pulmonary therapeutic strategies based on the Angiotensin-converting enzyme 2/angiotensin-(1–7)/mas receptor axis. Int J Hypertens. 2012;2012:5.
88.
Tan WSD, et al. Targeting the renin–angiotensin system as novel therapeutic strategy for pulmonary diseases. Curr Opin Pharmacol. 2018;40:9–17.PubMedCrossRef
89.
Srivastava P, et al. Imbalance between Angiotensin II-Angiotensin (1–7) system is associated with vascular endothelial dysfunction and inflammation in type 2 diabetes with newly diagnosed hypertension. Diabetes Metab Syndr. 2019;13(3):2061–8.PubMedCrossRef
90.
Cook JR, Ausiello J. Functional ACE2 deficiency leading to angiotensin imbalance in the pathophysiology of COVID-19. Rev Endocrine Metabolic Disord. 2021;10:1–20.
91.
Lanza K, et al. Covid-19: the renin–angiotensin system imbalance hypothesis. Clin Sci. 2020;134(11):1259–64.CrossRef
92.
Killerby ME, et al. Characteristics associated with hospitalization among patients with COVID-19—Metropolitan Atlanta, Georgia, March–April 2020. Morb Mortal Wkly Rep. 2020;69(25):790.CrossRef
93.
Metadata
Title
SNPs of ACE1 (rs4343) and ACE2 (rs2285666) genes are linked to SARS-CoV-2 infection but not with the severity of disease
Authors
Nahid Alimoradi
Moein Sharqi
Dena Firouzabadi
Mohammad Moein Sadeghi
Mohammad Iman Moezzi
Negar Firouzabadi
Publication date
01-12-2022
Publisher
BioMed Central
Published in
Virology Journal / Issue 1/2022
Electronic ISSN: 1743-422X
DOI
https://doi.org/10.1186/s12985-022-01782-6

Other articles of this Issue 1/2022

Virology Journal 1/2022 Go to the issue

Review

Therapeutic and diagnostic applications of nanoparticles in the management of COVID-19: a comprehensive overview

Research

Hepatitis C virus (HCV) infection among patients with sickle cell disease at the Korle-Bu teaching hospital

Research

The long non-coding RNA LNC_000397 negatively regulates PRRSV replication through induction of interferon-stimulated genes

Short report

Cold case: The disappearance of Egypt bee virus, a fourth distinct master strain of deformed wing virus linked to honeybee mortality in 1970’s Egypt

Research

Whole-genome sequencing and genetic characteristics of representative porcine reproductive and respiratory syndrome virus (PRRSV) isolates in Korea

Case Report

Central nervous system infection with Seoul Orthohantavirus in a child after hematopoietic stem cell transplantation: a case report
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits